Skip to content

Thiol Disulfide Balance in Cervix Cancer

Evaluation of Thiol Disulfide Balance in Cervix Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04258553
Enrollment
123
Registered
2020-02-06
Start date
2018-09-01
Completion date
2020-02-04
Last updated
2020-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervix Cancer, Oxidative Stress

Keywords

thiol disulfide hemostasis, screening, early diagnosis

Brief summary

The aim of this research is to evaluate thiol-disulfide balance in cervix cancer patients

Detailed description

To date various oxidative stress parameters were studied in patients with cervix cancer, however dynamic thiol disulfide hemostasis has not been previously investigated. The thiol-disulfide balance in the circulation will be measured by the automated system created by Erel & Neselioglu (1). References 1- Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 2014;47:326-32. doi:10.1016/j.clinbiochem.2014.09.026.

Interventions

DIAGNOSTIC_TESTDisulphide(μmol/L)

Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry

Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry

DIAGNOSTIC_TESTIschemia Modified Albumin(IU/mL)

The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).

Sponsors

Muğla Sıtkı Koçman University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

• Histopathologically confirmed diagnosis of cervix cancer

Exclusion criteria

* pulmonary disease * pulmonary hypertension * cardiac dysfunction * renal dysfunction * liver disease * chronic ischemia * systemic inflammation * concomitant malignancy * patients who use vitamin A,C or E (antioxidant vitamins) * patients who use smoke * patients who use drink alcohol * patients who use addictive for any drug

Design outcomes

Primary

MeasureTime frameDescription
native thiol/total thiol ratiopreoperative in the morning or preprandial for healthy volunteersnative thiol/total thiol ratio X (100 )
serum disulphide levelpreoperative in the morning or preprandial for healthy volunteersserum disulphide level in μmol/L
serum total thiol levelpreoperative in the morning or preprandial for healthy volunteersserum total thiol level in μmol/L
the disulphide/native thiol ratiopreoperative in the morning or preprandial for healthy volunteersthe disulphide/native thiol ratio X (100 )
disulphide/total thiol ratiopreoperative in the morning or preprandial for healthy volunteersdisulphide/total thiol ratio X (100 )
serum native thiol levelpreoperative in the morning or preprandial for healthy volunteersserum native thiol level in μmol/L

Secondary

MeasureTime frameDescription
total antioxidant capacity (TAC)preoperative in the morning or preprandial for healthy volunteersTAC in mmol trolox equivalent/L
Oxidative stress index (OSI)preoperative in the morning or preprandial for healthy volunteersOSI in mmol trolox/L.
ischaemia-modified albuminpreoperative in the morning or preprandial for healthy volunteersischaemia-modified albumin in IU/mL
total oxidant capacity (TOC)preoperative in the morning or preprandial for healthy volunteersTOC in mmol H2O2 equivalent/L

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026